Clinical Trial Update: A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy [Phase 1]

View source ↗

Summary

A Phase 1 study of ASP4070 in patients with Cedar Pollinosis has completed, showing safety and immunological response data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• ASP4070

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Cedar Pollinosis | Phase 1 | Status: COMPLETED